iRadimed (NASDAQ:IRMD) Sees Strong Trading Volume on Earnings Beat

iRadimed Corporation (NASDAQ:IRMD) saw strong trading volume on Friday following a better than expected earnings announcement. Approximately 172,292 shares traded hands during trading, an increase of 63% from the previous session’s volume of 105,746 shares.The stock last traded at $94.3770 and had previously closed at $95.21.

The medical equipment provider reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The business had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS.

iRadimed Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 28th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.20 per share. The ex-dividend date is Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is currently 43.72%.

iRadimed News Roundup

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
• Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
• Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, iRadimed currently has a consensus rating of “Buy” and an average price target of $120.00.

Insider Transactions at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $87.51, for a total value of $437,550.00. Following the completion of the transaction, the chief executive officer directly owned 2,175,000 shares in the company, valued at approximately $190,334,250. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 21,250 shares of company stock valued at $1,836,403 in the last 90 days. 34.60% of the stock is owned by insiders.

Institutional Trading of iRadimed

Institutional investors have recently modified their holdings of the company. Quarry LP bought a new position in shares of iRadimed during the 3rd quarter worth approximately $40,000. Farther Finance Advisors LLC lifted its position in iRadimed by 827.1% during the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 397 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 495 shares in the last quarter. CWM LLC boosted its stake in iRadimed by 19.5% in the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock valued at $64,000 after acquiring an additional 107 shares in the last quarter. Finally, Global Retirement Partners LLC acquired a new stake in iRadimed in the fourth quarter valued at approximately $85,000. 92.34% of the stock is currently owned by institutional investors.

iRadimed Price Performance

The company’s fifty day simple moving average is $94.54 and its 200-day simple moving average is $95.70. The firm has a market capitalization of $1.16 billion, a PE ratio of 50.76 and a beta of 0.90.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.